Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Kempharm Inc (KMPH)

Kempharm Inc (KMPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 215,243
  • Shares Outstanding, K 34,494
  • Annual Sales, $ 28,650 K
  • Annual Income, $ -8,560 K
  • 60-Month Beta 2.78
  • Price/Sales 7.14
  • Price/Cash Flow 23.76
  • Price/Book 2.06
Trade KMPH with:

Options Overview Details

View History
  • Implied Volatility 131.87% ( +20.51%)
  • Historical Volatility 70.18%
  • IV Percentile 66%
  • IV Rank 33.77%
  • IV High 255.21% on 06/16/22
  • IV Low 68.99% on 06/06/22
  • Put/Call Vol Ratio 0.70
  • Today's Volume 395
  • Volume Avg (30-Day) 301
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 40,790
  • Open Int (30-Day) 40,244

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.16
  • Low Estimate -0.21
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -216.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.27 +18.41%
on 09/01/22
6.92 -9.83%
on 09/15/22
+0.88 (+16.42%)
since 08/30/22
3-Month
4.41 +41.50%
on 07/01/22
6.92 -9.83%
on 09/15/22
+1.78 (+39.91%)
since 06/30/22
52-Week
4.00 +56.00%
on 05/12/22
10.80 -42.22%
on 10/22/21
-3.09 (-33.12%)
since 09/30/21

Most Recent Stories

More News
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study

KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.

KMPH : 6.24 (+5.23%)
AERI : 15.13 (+0.07%)
SLNO : 1.6700 (+2.45%)
ACER : 1.3900 (-0.71%)
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

DERM : 2.46 (-1.99%)
KMPH : 6.24 (+5.23%)
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...

KMPH : 6.24 (+5.23%)
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CTIC : 5.82 (+3.37%)
KMPH : 6.24 (+5.23%)
Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LYEL : 7.33 (-1.08%)
KMPH : 6.24 (+5.23%)
KemPharm to Report Second Quarter 2022 Financial Results

CELEBRATION, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...

KMPH : 6.24 (+5.23%)
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference

CELEBRATION, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...

KMPH : 6.24 (+5.23%)
KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting

CELEBRATION, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company...

KMPH : 6.24 (+5.23%)
Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?

Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the...

ACRS : 15.74 (+6.21%)
KMPH : 6.24 (+5.23%)
KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion

Three clinical studies demonstrated serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related...

KMPH : 6.24 (+5.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303...

See More

Key Turning Points

3rd Resistance Point 6.79
2nd Resistance Point 6.56
1st Resistance Point 6.40
Last Price 6.24
1st Support Level 6.01
2nd Support Level 5.78
3rd Support Level 5.62

See More

52-Week High 10.80
Fibonacci 61.8% 8.20
Fibonacci 50% 7.40
Fibonacci 38.2% 6.60
Last Price 6.24
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar